Korea Professor Do-Youn Oh discusses advances in gastrointestinal oncology, reflecting on the practice-changing TOPAZ-1 trial, Korea’s strengths in clinical research, and the importance of biomarker-driven therapies. She shares her approach to investigator-led drug development, industry collaboration, and translational research, while outlining emerging opportunities in ADCs, immunotherapy, AI, and multi-omics to improve…
See our Cookie Privacy Policy Here